Home / Reports / Cost reductions due to biosimilars in Europe

Cost reductions due to biosimilars in Europe Posted 07/08/2015

Biosimilars have been approved in the European Union since 2006 in the classes of erythropoietin (EPO), human growth hormone (HGH), granulocyte colony-stimulating factor (G-CSF) and anti-tumour necrosis factor (anti-TNF).  Despite the fact that they have been in use since 2006, the prices for EPO, HGH and G-CSF classes of drugs in some countries have not reduced by as much as some might have expected. There is also a significant variation between different countries in Europe [1].

This variation is mostly attributed to differences in the healthcare systems between different countries. In some countries this can mean that therapy costs may not always have reduced after the introduction of biosimilars, see Figure 1.

Therapy costs in Europe in 2013 compared to 2006 have shown changes of -75% for EPO in Croatia to an incredible 600% increase in the cost of G-CSF therapy in Romania. In fact, despite Eastern European countries leading the way in biosimilars penetration, they have experienced some of the largest relative increases in the cost of biologicals therapy across Europe.

Editor’s Comment
If you would like to receive a high-resolution copy* of Figure 1 please send us an email.

*For profit organizations subjected to a fee

Related articles
Biosimilars penetration in Europe varies widely

Biosimilar events from 2013 to 2015

Reference
1. Rickwood S. Perspectives on the evolving biosimilars landscape. 13th EGA-European Biosimilars Group Conference; 23–24 April 2015; London, UK.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Comments (0)